FDA Memo Discussed Pulling Vioxx Based On HMO Study
This article was originally published in The Pink Sheet Daily
Executive Summary
An FDA internal memo discusses pulling Merck's Vioxx (rofecoxib) based on the results of a retrospective study sponsored by the agency and Kaiser Permanente